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Introduction

Presentation of the Case

Genetic disorders are widely
misunderstood in our society and can
lead to early mortality. Marfan
syndrome (MFS) is a genetic disorder
that affects connective tissue
(Harris, Croce, & Tian, 2014).
Antoine Marfan, a French pediatrician,
first described this disease in 1896
(Elshershari & Harris, 2014).
MFS can manifest in several different
organ systems. The cardiovascular
complications of aortic dilation
and dissection often account for the
morbidity
associated with this disease
(Harris et al., 2014).
Understanding the inheritance,
pathophysiology,
and treatment of MFS is important for
the advanced practice nurse (APN).
Prevalence of the disease is
approximately two per
10,000 individuals, but it is thought
that MFS is under diagnosed and
authorities suspect
MFS may affect one in 3,000
(Pitcher, Emberson, Lacro, Sleeper,
& Stylianou, 2015).
MFS is most notable for affecting
Abraham Lincoln and causing
the death of Flo Hyman, a member of
the 1986 US Olympian team
(Davis, Dyar, Vargas, & Grossfeld,
2015). By obtaining a detailed health
history of all athletes and recognizing
the rare phenotype expressed by
children withMFS, the APN can
prevent the mortality associated with
MFS, especially in the athletic
population.

Lamar has played
basketball his entire life. His
height, long arms, and long
fingers have propelled him to
the top of every team and
league he has ever
participated in. Lamar is 6’8”,
has bilateral lens
discoloration, and slight
scoliosis of the spine. As a
child he also had a detached
retina, which required repair.
Lamar has to have an
echocardiogram done as part
of his yearly physical to play
division one basketball.
After the screening, he is
referred to a cardiologist
because the test reveals a
dilated aortic root. Genetic
testing reveals a mutation in
the gene FBN1, found on
chromosome 15. These factors
as scored by the Ghent
Criteria, are enough to
diagnose Lamar with Marfan
syndrome. The phenotype of
Marfan syndrome can be very
variable (Braverman, 2015).

Pathophysiology

Significance of Pathophysiology

The underlying
pathophysiology of Lamar’s
diagnosis revolves around
the
alteration of the FBN1 gene.
The disease is
usually transmitted in an
autosomal dominant fashion.
FBN1 is responsible for
encoding the glycoprotein
fibrillin. Fibrillin is the
structural component of
microfibrils. Microfibrils
serve as building blocks in
the human body and
ligaments
found in eye lenses, the aorta,
and other connective tissues
(Chen, 2015). Defects in
fibrillin cause weakness in
these
tissues and hence the
abnormalities observed
in patients with this disease.
Transforming growth factorbeta receptor (TGFBR) also
plays an important role in
Marfans. Fibrillin-1 binds to a
form of TGFBR
and keeps it sequestered
throughout the body.
Insufficient amounts of
fibrillin cause an excess of
TGFBR in the lungs, heart
valves,
and aorta. It is unclear how
high levels
of TGFBR cause the pathology
associated
with the disease.

The significance of this pathophysiology explains the
symptoms commonly seen. The defect in fibrillin coupled with
the overabundance of TGFBR causes problems in connective
tissue throughout the body (Greenemeir, 2014). In Lamar’s
case, the dilated aortic root can lead to an emergent
situation known as aortic dissection. This can be a lifethreatening emergency. Lamar suffered a retinal detachment as
a young child because of Marfans, and the inability of the
connective tissue of the eye to hold his retina in place
(Marfans Research Foundation, 2009). As people age and
weaken with Marfan syndrome, the more likely they are to
suffer consequences as connective tissue weakens as well.

Conclusion
When diagnosed, Marfan patients can have a normal life
expectancy with crucial lifestyle modifications in place.
Undiagnosed, Marfan syndrome can unfortunately lead to an early,
unexpected death. The APN has a responsibility to inform
themselves on the symptoms expressed by this rare disease.
Becoming a knowledgeable APN can benefit the young athletes in
their community.

Nursing Implications
The most crucial step for the
advanced practice nurse (APN)
in dealing with Marfan syndrome
is the diagnosis. Becoming
familiar with the Ghent criteria
can help the APN recognize the
signs of Marfan in the general
public and athletes in particular.
The Ghent nosology involve a
scoring system where systemic
features of Marfans are graded
(Wright & Connolly, 2015). In
athletes with Marfan-like
qualities of superior height and
extended extremity length, an
echocardiogram should be
performed. This test can give the
APN a view of the heart using
sound waves (Greenemeier,
2014). Gene testing can be
performed, but is usually only
done so in families that have a
high occurrence of Marfan. Once
the disease is diagnosed the APN
can focus on the medical
management of the disease with
the patient. Physical activity
should be modified in order to
reduce the stress placed on the
aorta (The Marfan Foundation,
2015). Medications such as betablockers or angiotensin receptor
blockers are prescribed to lower
the workload of the heart or
aorta. The APN needs to stress to
athletes and their families that
this does not reduce the risk of
strenuous exercise on the aorta.
The APN must keep in mind the
emotional toll that this may place
on an athlete. Removing their
ability to participate in
strenuous sports such as
basketball may result in
depression.
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